The University of Texas MD Anderson Cancer Center Anderson West 3 Patient Advocacy - 13 0612900BD Introduction to MD Anderson MD Anderson is known throughout the world for high-quality cancer care, research, academic programs and prevention services. Since its establishment in 1941, MD Anderson has made major contributions to improve the outlook for cancer patients everywhere. MD Anderson was one of the first three federally designated comprehensive cancer centers by the National Cancer Act of 1971. A survey of health professionals has routinely ranked MD Anderson as one of the two premier cancer centers in the nation for the past eight years. Over 55,000 persons annually seek care at MD Anderson. The team approach to cancer care, pioneered at MD Anderson, has been strengthened by consolidating specialty clinics into multi-disciplinary care centers that allow patients to receive more ambulatory care and treatment in a single location. MD Anderson offers one of the largest bone marrow and stem cell transplantation programs, as well as clinical trials to improve existing therapies. Teams of clinical specialists collaborate with scientists on problems of common interest and test theories that shorten the application of better treatment methods. Translational research studies are responsible for the promising field of chemoprevention, which uses synthetic vitamins to reverse pre-malignant lesions and halt the recurrence of some cancers, and for innovative gene therapy strategies being evaluated for several forms ofcancer. With faculty and staff working in more than 30 buildings in the greater Houston area and in central Texas, MD Anderson is the largest freestanding cancer center in the world. The physical plant covers more than 11 million square feet, featuring the latest equipment and facilities to support growing needs in outpatient and inpatient care, research, prevention and education. It includes inpatient hospital facilities with 571 beds. Construction projects include the addition of 12 floors that can accommodate more than 300 new inpatient beds in Alkek Hospital on the North Campus; two new research buildings on the South Campus that will house the Center for Advanced Biomedical Imaging Research and Center for Targeted Therapy as part of the McCombs Institute; and MD Anderson's first facility on its Mid Campus, a 25-story building to support current office space and future growth needs. In addition to its main campus in the Texas Medical Center and two research campuses in Bastrop County, Texas, MD Anderson has developed a number of local, national and international affiliations RFx Overview PRE-PROPOSAL CONFERENCE: A pre-proposal conference will be held at the time and location described below. July 24th 2013, 1:30 PM Local Time The University of Texas MD Anderson Cancer Center Fannin Holcombe Building 6900 Fannin Boulevard Room FHBM.102 Houston, Texas 77030 The Anderson West 3 corridor is part of the Access Pathway at the D Elevators. The project location is between the in-patient zone, Lutheran and Alkek, to the west, and the out-patient zone, Clark Clinic, to the east. The space on Anderson West 3 is the scope of work for this project and it is approximately 4,000 DGSF. The overall project goal for Patient Advocacy is to cluster functions in one geographic area by creating a new “front door” for patients and family. This includes the construction of a new reception and consultation area for patients and families, as well as a designated home for Patient Advocate staff and functions. This project will also provide an opportunity to upgrade the existing HVAC infrastructure for the wing. This project proposes a new air handling unit to replace the existing fan coil unit. Questions related to this RFP must be sent via the information request form. All questions must be received no later than July 26, 2013 4:00 PM. Questions received after this time will not be accepted. Questions will not be answered via telephone. All answers to any questions or inquiries will be posted on the webpage for all Suppliers to access. It is the intent of MD Anderson to respond to all questions and concerns; however, MD Anderson shall reserve the right to decline to respond to any question or concern. It is important to note that the supplier or suppliers selected to develop MD Anderson's RFP are not automatically qualified to engage with the Institution for purposes of implementing the recommended strategy or solutions. The engagement of contracted services for implementation can, at MD Anderson's discretion, be solicited via a second and separate Request for Proposal. Standard Riders and Agreements AA RFP.pdf AAA ADDENDUM 1 to RFP.pdf AAA Addendum 1 Pre-bid Sign in Sheets.pdf AAAA ADDENDUM 2 to RFP.pdf AAAA Addendum 2 Responses to Requests for Information (RFI's).pdf AAAA Addendum 2 Sign in Sheets from Walk Through July 30, 2013.pdf AAAAA ADDENDUM 3 to RFP.pdf AAAAA Addendum 3 Responses to Requests for Information (RFI's).pdf BB Attachment A Draft Agreement and Bonds.pdf CC Attachment B Rider 1 to the Agreement.pdf DD Attachment C Rider 104A Hub Plan.pdf EE Attachment D Rider 105 Affirmations and Warranties.pdf FF Attachment E Rider 106 Premises Rules.pdf GG Attachment F Rider 107 Travel Policy.pdf HH Attachment G Rider 116 Invoice Payment Requirements.pdf II Attachment H Rider 117 Institutional Policies.pdf JJ Attachment I Request for Information.pdf KK Attachment J Pricing and Delivery Proposal.pdf LL Attachment K 2010 UGC.pdf ***Interested suppliers should also note that Subcontracting Opportunities are probable in connection with this solicitation. Please review the HUB Subcontracting Tip Sheet ***RFx refers to RFP, RFQ, RFI, ITB, etc. Return to Supply Chain Management List of Current Bids.

Bid Protests Not Available